Compare iShares MSCI Canada (TSX) (EWC) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Eli Lilly And Co — how do they compare? iShares MSCI Canada (TSX) trades at $58.3 (market cap $6.99B), while Eli Lilly And Co trades at $1,167.38 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 148.8× iShares MSCI Canada (TSX)'s market cap, and Eli Lilly And Co pays a 0.59% dividend while iShares MSCI Canada (TSX) pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Canada (TSX) for 57 Days and Eli Lilly And Co for 93 Days on average.
| EWC | LLY | |
|---|---|---|
Market Cap | $6.99B | $1.04T |
Volume | 1,625,847 | 3,064,878 |
Sector | Broad Market / Factor | Health |
52-Week High | $62.64 | $1.28K |
52-Week Low | $49.72 | $799.57 |
Typical Hold Time | 57 Days | 93 Days |
Enterprise Value | — | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC is trading at $57.94, down 2.1% with a bearish technical signal as moving averages indicate selling pressure while oscillators remain neutral. The stock shows oversold conditions with RSI readings below 30, suggesting potential for near-term bounce. Recent news highlights Canada's trade tensions with the US and potential EU associate membership discussions creating market uncertainty.
The outlook remains cautious given trade policy risks and technical weakness, though oversold conditions may provide short-term opportunities. Key risks include US-Canada trade disputes and economic sensitivity to external shocks, while potential EU alignment could offer diversification benefits if negotiations progress favorably.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beats, robust revenue growth to $65.18B in 2025, and a net income margin of 33.53% highlight operational strength. Positive news flow centers on next-generation weight-loss drugs, with analyst consensus bullish and a price target of $1,350.
Outlook remains positive given pipeline catalysts in obesity/diabetes markets, though high valuations (P/E 39.9) and rising debt levels pose risks. Competitive intensity and regulatory scrutiny are watchpoints, but institutional support and earnings momentum underpin further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
